ARKK Holdings of IOVA
Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. is a biotechnology company that specializes in developing tumor-infiltrating lymphocyte (TIL) therapy, a type of cancer immunotherapy that harnesses the patient's own immune cells to treat cancer. The company generates revenue primarily through collaborations, partnerships, and potential future product sales of its TIL therapy once it obtains regulatory approval and commercialization.
Trades of IOVA in ARKK
The ten most recent trades of Iovance Biotherapeutics in the ARKK ETF.View all trades
Date | Direction | Market Value | % of Position | % of ETF |
|---|---|---|---|---|
| Feb 01, 2022 | Sell | $2,538 | 100.00% | 0.00% |
| Jan 18, 2022 | Sell | $48,771 | 2,188.00% | 0.00% |
| Jan 12, 2022 | Sell | $2,734,200 | 5,300.66% | 0.02% |
| Jan 06, 2022 | Sell | $37,830,399 | 1,230.27% | 0.26% |
| Jan 05, 2022 | Sell | $2,113,303 | 4.80% | 0.01% |
| Jan 04, 2022 | Sell | $6,150,000 | 12.59% | 0.04% |
| Jan 03, 2022 | Sell | $17,537,905 | 30.65% | 0.11% |
| Dec 30, 2021 | Sell | $3,995,166 | 4.87% | 0.02% |
| Dec 27, 2021 | Sell | $558,727 | 0.64% | 0.00% |
| Dec 17, 2021 | Sell | $2,904,972 | 3.59% | 0.02% |